Aquestive Therapeutics Inc

Research Aquestive Therapeutics Inc (AQST) on Bullrun: market cap USD 637.60M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 637.60M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 44.55M-USD 83.78M-USD 52.99M58.3%-0.78USD 121.17MUSD 45.00M-USD 33.66M
FY2024USD 57.56M-USD 44.14M-USD 35.92M69.0%-0.51USD 71.55MUSD 45.00M-USD 60.16M
FY2023USD 50.58M-USD 7.87M-USD 7.38M58.8%-0.13USD 23.87MUSD 45.00M-USD 106.49M
FY2022USD 47.68M-USD 54.41M-USD 10.84M59.3%-1.12USD 27.27MUSD 51.50M-USD 118.55M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 637.60Mn/an/an/a
20252025-12-31USD 788.41Mn/an/an/a
20242024-12-31USD 325.43Mn/an/an/a
20232023-12-29USD 134.87Mn/an/an/a
20222022-12-30USD 48.74Mn/an/an/a
20212021-12-31USD 160.38Mn/an/an/a

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Aquestive Therapeutics Inc's market cap?

Aquestive Therapeutics Inc's market capitalization is USD 637.60M.

What does Aquestive Therapeutics Inc do?

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film.